Latest Medical Devices News

Page 4 of 67
Orthocell’s flagship Remplir nerve-repair product gained ground in the US and Thailand during the September quarter, even as total revenue slipped from the June period. The company reported A$39 million in available funds and said it does not currently expect to raise additional capital.
Ada Torres
Ada Torres
22 Oct 2026
EBR Systems has submitted its WiSE wireless cardiac pacing system for Australian regulatory approval, opening a potential second commercial market after the United States. The application has entered a priority review pathway, but neither approval nor an assessment timetable is guaranteed.
Victor Sage
Victor Sage
20 Oct 2026
Medical Developments International CEO Brent MacGregor is stepping down after six years, with CFO Anita James taking over as interim CEO from 15 October. The board has begun searching for a permanent successor as MacGregor prepares to return to North America.
Ada Torres
Ada Torres
15 Oct 2026
Biotron has appointed Glenn Gilbert as chief executive and executive director, bringing more than two decades of pharmaceutical, medical device and diagnostics experience to the company’s SedRx and antiviral programs. His package combines a $250,000 salary with up to 100 million performance-based options and $230,000 in milestone-linked cash bonuses.
Victor Sage
Victor Sage
14 Oct 2026
ReNerve has received supportive FDA feedback on the preclinical and testing pathway for its NervAlign Nerve Guide Matrix. The guidance sharpens the route towards a US submission, but does not amount to clearance and leaves the submission timetable open.
Victor Sage
Victor Sage
14 Oct 2026
Memphasys has reported record September-quarter invoiced revenue of A$211,000 as its Felix fertility device moves into more international markets. The commercial progress comes alongside A$3.5 million in funding, but the loan still requires shareholder approval for conversion into notes.
Ada Torres
Ada Torres
13 Oct 2026
Orthocell says Remplir was placed successfully in five complex robotic prostatectomy cases, with no device-related complications reported over approximately 12 months. The preliminary results will guide a larger prospective trial ahead of a planned US expansion for the nerve repair product.
Ada Torres
Ada Torres
13 Oct 2026
EBR Systems reported 40 WiSE commercial implants in Q3, down from 46 in Q2 and below its prior forecast, as leadership changes and a sales strategy reset disrupted activity. Higher Medicare reimbursement and progress at its new manufacturing facility offer potential offsets, but both remain dependent on execution and regulatory approval.
Victor Sage
Victor Sage
12 Oct 2026
Medical Developments International returned to EBIT profitability in FY26 as Penthrox volumes strengthened across Australian hospitals and Europe. The company now faces the less glamorous test of converting regulatory progress into repeatable demand while absorbing weaker Respiratory sales and new amortisation costs.
Ada Torres
Ada Torres
9 Oct 2026
Imricor has completed FDA review of the largest module in its US Premarket Approval application, with no deficiencies found in its ablation catheter or irrigation tubing. One operating-system issue remains for the RF-5000 System, but the company says it has already updated the software and is preparing its response.
Victor Sage
Victor Sage
8 Oct 2026
ReNerve’s October AGM presentation points to sharply higher sales, a growing US distribution network and a broader nerve repair pipeline. The company is also progressing a 240-patient NervAlign clinical study while relying on a $5 million RiverFort funding facility to support expansion.
Victor Sage
Victor Sage
5 Oct 2026
CONNEQT Health delivered sharp FY26 revenue growth and reduced its statutory loss as Pulse sales and clinical subscriptions expanded. But the ASX-listed medtech group ended the year with negative net assets, heavy cash burn and a material uncertainty over its ability to continue as a going concern.
Victor Sage
Victor Sage
30 Sept 2026

Browse the archive

Full archive